VTYX 241220 4.00C (VTYX241220C4000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

VTYX241220C4000

Watchlist

0.05
-0.05-50.00%

15min DelayClose Dec 13 16:00 ET

0.05High0.05Low

Intraday

5D
Daily

News

Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k
Yahoo FinanceDec 14 08:34 ET
Founder of Ventyx Biosciences Picks Up 30% More Stock
Simply Wall StNov 28 05:15 ET
Morgan Stanley Maintains Ventyx Biosciences(VTYX.US) With Hold Rating
Moomoo NewsNov 27 06:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Ventyx Biosciences (VTYX)
TipRanksNov 27 06:20 ET · Ratings
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 43% Over the Past Week
Simply Wall StNov 27 05:12 ET
Neurogene and Ventyx Biosciences Rises After Insider Buying by Executives
Seeking AlphaNov 26 12:15 ET

Comments

Tonyco

Nov 29 19:20

Columns Pay me

Here have some gifts, my weekend work so far:
$Yalla (YALA.US)$ diversity outside Asia/us, expanding reach
$NexGel (NXGL.US)$ specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives
$Lumen Technologies (LUMN.US)$ ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels
$Rezolute (RZLT.US)$ also approaching oversold
$Ventyx Biosciences (VTYX.US)$ impressiv...

Jaguar8

Oct 15 08:03

NEWS

$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...

Jaguar8

Sep 23 12:35

Ventyx Biosciences Price Target Maintained With a $6.00/Share by HC Wainwright & Co

$Ventyx Biosciences (VTYX.US)$

Stock_Drift

Sep 23 08:00

9/23/24 👀’s on_watchlist. 🚨🚨*not financial advice*

$Nuvve (NVVE.US)$ $Treasure Global (TGL.US)$ $Expion360 (XPON.US)$ $Black Diamond Therapeutics (BDTX.US)$ $Ventyx Biosciences (VTYX.US)$
📊⚡️📊

Jaguar8

Sep 23 07:26

“Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of $3.8243 per share of common stock”

$Ventyx Biosciences (VTYX.US)$